These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 34433022)
21. N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer. Su Y; Li J; Witkiewicz AK; Brennan D; Neill T; Talarico J; Radice GL Oncogene; 2012 Oct; 31(41):4484-9. PubMed ID: 22158044 [TBL] [Abstract][Full Text] [Related]
22. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028 [TBL] [Abstract][Full Text] [Related]
23. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Zhang Y; Zoltan M; Riquelme E; Xu H; Sahin I; Castro-Pando S; Montiel MF; Chang K; Jiang Z; Ling J; Gupta S; Horne W; Pruski M; Wang H; Sun SC; Lozano G; Chiao P; Maitra A; Leach SD; Kolls JK; Vilar E; Wang TC; Bailey JM; McAllister F Gastroenterology; 2018 Jul; 155(1):210-223.e3. PubMed ID: 29604293 [TBL] [Abstract][Full Text] [Related]
24. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033 [TBL] [Abstract][Full Text] [Related]
25. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115 [TBL] [Abstract][Full Text] [Related]
26. Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-Kras Hu S; Pan L; Shangguan J; Figini M; Eresen A; Sun C; Wang B; Ma Q; Hu C; Yaghmai V; Velichko Y; Yang J; Zhang Z J Immunol Methods; 2019 Feb; 465():1-6. PubMed ID: 30468734 [TBL] [Abstract][Full Text] [Related]
27. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Goehrig D; Nigri J; Samain R; Wu Z; Cappello P; Gabiane G; Zhang X; Zhao Y; Kim IS; Chanal M; Curto R; Hervieu V; de La Fouchardière C; Novelli F; Milani P; Tomasini R; Bousquet C; Bertolino P; Hennino A Gut; 2019 Apr; 68(4):693-707. PubMed ID: 30415234 [TBL] [Abstract][Full Text] [Related]
28. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479 [TBL] [Abstract][Full Text] [Related]
29. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536 [TBL] [Abstract][Full Text] [Related]
31. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Seifert L; Werba G; Tiwari S; Giao Ly NN; Nguy S; Alothman S; Alqunaibit D; Avanzi A; Daley D; Barilla R; Tippens D; Torres-Hernandez A; Hundeyin M; Mani VR; Hajdu C; Pellicciotta I; Oh P; Du K; Miller G Gastroenterology; 2016 Jun; 150(7):1659-1672.e5. PubMed ID: 26946344 [TBL] [Abstract][Full Text] [Related]
32. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. Schofield HK; Zeller J; Espinoza C; Halbrook CJ; Del Vecchio A; Magnuson B; Fabo T; Cali Daylan AE; Kovalenko I; Lee HJ; Yan W; Feng Y; Karim SA; Kremer DM; Kumar-Sinha C; Lyssiotis CA; Ljungman M; Morton JP; Galbán S; Fearon ER; Pasca di Magliano M JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367463 [TBL] [Abstract][Full Text] [Related]
33. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001 [TBL] [Abstract][Full Text] [Related]
34. Mutant p53 regulates Survivin to foster lung metastasis. Tang Q; Efe G; Chiarella AM; Leung J; Chen M; Yamazoe T; Su Z; Pitarresi JR; Li J; Islam M; Karakasheva T; Klein-Szanto AJ; Pan S; Hu J; Natsugoe S; Gu W; Stanger BZ; Wong KK; Diehl JA; Bass AJ; Nakagawa H; Murphy ME; Rustgi AK Genes Dev; 2021 Apr; 35(7-8):528-541. PubMed ID: 33737385 [TBL] [Abstract][Full Text] [Related]
35. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Bailey JM; Hendley AM; Lafaro KJ; Pruski MA; Jones NC; Alsina J; Younes M; Maitra A; McAllister F; Iacobuzio-Donahue CA; Leach SD Oncogene; 2016 Aug; 35(32):4282-8. PubMed ID: 26592447 [TBL] [Abstract][Full Text] [Related]
36. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer. Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580 [TBL] [Abstract][Full Text] [Related]
37. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion. Yang Y; Stang A; Schweickert PG; Lanman NA; Paul EN; Monia BP; Revenko AS; Palumbo JS; Mullins ES; Elzey BD; Janssen EM; Konieczny SF; Flick MJ Cancer Res; 2019 Jul; 79(13):3417-3430. PubMed ID: 31048498 [TBL] [Abstract][Full Text] [Related]
38. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer. Weyandt J Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272 [TBL] [Abstract][Full Text] [Related]
39. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607 [TBL] [Abstract][Full Text] [Related]
40. Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer. Feng M; Wang F; Liu X; Hao T; Zhang N; Deng M; Pan Y; Kong R Cancer Biol Med; 2023 May; 20(6):421-37. PubMed ID: 37184030 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]